Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
$ 0.12
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Greatly overvalued vs peers
Data is available to registered users only
Data is available to registered users only
About
Hadasit Bio-Holdings Ltd operates in the biotechnology industry in Israel. It primarily focuses on the therapeutic areas, including oncology, regenerative medicine, and inflammatory disease. The company offers ProtAb, an immunotherapeutic monoclonal antibody for the treatment of autoimmune inflammatory diseases. Hadasit Bio-Holdings Ltd was founded in 2005 and is based in Jerusalem, Israel.
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.
Data is available to registered users only
Buy
Sell